HighLife Medical

HighLife Medical is a Paris-based medtech company founded in 2010, specializing in innovative transcatheter solutions for heart valve diseases, particularly mitral regurgitation. The company develops the HighLife TSMVR (Trans-septal Mitral Valve Replacement) system, a breakthrough device designed for patients with moderate to severe mitral regurgitation. This system enables trans-septal delivery on a beating heart, offering a minimally invasive alternative to traditional open-heart surgery for high-surgical-risk patients. HighLife has achieved significant regulatory milestones, including FDA Breakthrough Device Designation and CE Mark approval. The company operates with fewer than 25 employees across Europe, the USA, and Australia, with partnerships extending to China. Beyond device manufacturing, HighLife provides clinical support and physician training to enhance treatment accessibility and patient outcomes.